Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03768544
Other study ID # SIRUL 118715
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 11, 2019
Est. completion date February 24, 2023

Study information

Verified date October 2023
Source Laval University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Few older adults receive treatment for Generalized Anxiety Disorder (GAD) despite a high prevalence in this population and significant associated health care costs. Although older adults generally prefer psychotherapy to medication for help with anxiety, face-to-face psychotherapy is difficult to access for many of them. Psychological guided self-help (GSH), which patients use by themselves at home under the supervision of a licensed mental health provider (e.g., psychologist), has been shown to be effective. However, the capacity of our health care system to respond adequately to the mental health needs of seniors has been questioned and cost-effective solutions are required. Because the therapist's role in GSH is limited to supporting the patient, it is conceivable that this role could be assumed by trained and supervised lay providers (LP) instead of licensed providers. If this approach is effective, it could help provide many older adults with much needed mental health treatment at a lower cost. The main objective of this project is to evaluate the effectiveness of GSH guided by LP for GAD in older adults. Participants will be assigned randomly to an experimental group, which will receive treatment immediately, or to a control group whose treatment will be delayed. Data will be obtained through clinician evaluations and self-assessment questionnaires. They will include socio-demographic characteristics, symptoms of GAD, variables related to anxiety, such as depression and sleep difficulties, and participants' perception of treatment. For the experimental group, data collection will take place at four different times: before treatment begins, after treatment ends, and at 6 and 12 months after the end of treatment. Control group participants will be assessed on three occasions: before and after the waiting period and after receiving treatment. The efficacy of GSH will be established by comparing the change in the two groups on the main variables. We will also identify the characteristics of patients associated with improvement during treatment and document their perception of treatment.


Description:

Few older adults with Generalized Anxiety Disorder (GAD) receive treatment although it is one of the most prevalent anxiety disorders in this population and involves significant health care costs. Studies show that older adults generally prefer psychotherapy and find it more acceptable than medication for help with anxiety. Unfortunately, face-to-face psychotherapy is difficult to access for many of them. Guided self-help (GSH) is an alternative to psychotherapy which requires that the patient take home a standardized psychological treatment and work through it more or less independently. The role of the therapist is primarily of supportive nature and the amount of contact between the patient and therapist is minimized. There is evidence that GSH based on the principles of cognitive-behavioral therapy (GSH-CBT) and guided by a licensed mental health provider is effective for treating GAD in older adults. However, the capacity of our health care system to respond adequately to the mental health needs of older adults has been questioned and cost-effective solutions are required to meet the needs of a rapidly aging population. Because the therapist's role in GSH-CBT is limited to supporting the patient, it is conceivable that this role could be assumed by trained and supervised lay providers (LP) instead of licensed providers. LP are generally providers with no post-graduate training in a specialized mental health program. The main goal of the study is to evaluate the efficacy of GSH-CBT guided by LP for GAD in older adults. Secondary goals are to identify the characteristics of patients associated with improvement during treatment and to document perception of treatment by patients and LP. We will conduct a multisite randomized controlled trial comparing an experimental group receiving GSH-CBT guided by LP to a wait-list control group. LP training will include readings, didactic training, and role plays. LP will be supervised throughout the project by licensed psychologists. Treatment will last 15 weeks and be based on a participant's manual. Weekly telephone sessions with LP (30 minutes maximum) will be limited to providing support. Data will be obtained through clinician evaluations and self-assessment questionnaires. They will include symptoms of GAD and variables related to anxiety, such as depression. For the experimental group, measurements will take place at pre- and post-treatment and at 6 and 12 months post-treatment. For the control group, three evaluations are planned: two pre-treatment evaluations (before and after the waiting period) and after receiving treatment (post-treatment). The efficacy of GSH-CBT will be established by comparing the change in the two groups on the main variables. This project will provide evidence on the effectiveness of a novel approach to treat GAD in older adults. If effective, it may be implemented on a larger scale and provide many older adults with much needed mental health treatment through an expanded workforce.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date February 24, 2023
Est. primary completion date February 24, 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - 60 years of age or older - meet at least criteria for subthreshold GAD at screening based on items of the Worry and Anxiety Questionnaire - meet DSM-5 criteria for primary threshold or subthreshold GAD - be able to read and speak French and to use the telephone without difficulty - if an anxiety medication is used, commit to maintaining the type of medication or dose during eight weeks prior to treatment and during the protocol. Exclusion Criteria: - a disabling physical disorder that is not adequately controlled (e.g., acute heart disease, recent stroke) - the presence of a substance use disorder - presenting a bipolar disorder or symptoms of a psychotic disorder - having significant cognitive impairment (score of less than 22 on the Telephone version of the Mini-Mental State Examination) - currently receiving or having received psychotherapy for anxiety over the last six months.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Self-help guided by a lay provider
Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
Waiting list where participants wait for delayed treatment
Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.

Locations

Country Name City State
Canada Centre de recherche de l'Institut universitaire de gériatrie de Montréal Montréal Quebec
Canada École de psychologie, Université Laval Québec Quebec
Canada Département de psychologie, Université de Sherbrooke Sherbrooke Quebec

Sponsors (5)

Lead Sponsor Collaborator
Laval University Canadian Institutes of Health Research (CIHR), CIUSSS du Centre-Sud-de-l'Île-Montréal, Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke, Integrated University Health and Social Services Center of the Capitale-Nationale

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation of treatment by participants Measures participant's perception of treatment. 19 statements covering various aspects of treatment (modules, readings, exercises, telephone sessions, workload, organization and duration of treatment, and its usefulness). Each statement is evaluated on a four-point scale ranging from "strongly agree" to "absolutely disagree". A fifth possible answer, 'does not apply', is also provided. Post treatment (15 weeks)
Other Questionnaire of behavioral manifestations linked to anxiety Twenty-four items evaluating six behaviors related to generalized anxiety, namely reassurance seeking, avoidance, control, procrastination, overplanning and checking. Items are rated on a five point Likert scale Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Other Nine items relating to COVID-19 These items were added to describe the reality of the participants while considering the effects of the pandemic on their anxiety. Five questions are framed as "yes or no" with an open-ended description of their answer choice whereas four items are rated on a five-point Likert scale. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Primary Change in Penn State Worry Questionnaire 16 items rated on a scale ranging from 1 to 5. A higher total score indicates a greater tendency to worry. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Primary Change in GAD-7 7 items answered on a scale ranging from 0 to 3. A higher total score suggests greater severity. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Intolerance to Uncertainty Inventory 27 items rated on a scale ranging from 1 to 5. A higher total score suggests higher intolerance to uncertainty. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Negative Problem Orientation Questionnaire 12 items rated on a scale ranging from 1 to 5. A higher total score suggests more negative attitudes toward problems. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Cognitive Avoidance Questionnaire 25 items rated on a scale ranging from 1 to 5. A higher total score suggests more likely use of cognitive avoidance. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Why Worry Questionnaire 25 items rated on a scale ranging from 1 to 5. A higher total score suggests a greater belief that worrying is useful. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Geriatric Anxiety Inventory 20 items rated as "agree" or "disagree". Minimum score = 0; Maximum score = 20. A higher total score is indicative of greater severity of symptoms. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Geriatric Depression Scale 30 items rated as "yes" or "no". Minimum score = 0; Maximum score = 30.A higher total score is indicative of greater severity of symptoms. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Insomnia Severity Index 7 items rated on a scale ranging from 1 to 4. A higher total score suggests more severe insomnia. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Sheehan Disability Scale Three self-rated items of family, work, and social impairment rated on a scale ranging from 0 to 10. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in Mini-Mental State Examination, telephone version Items on orientation to time and place, registration, attention, recall, and language. Scores vary between 0 and 26 with higher scores indicating better cognitive functioning. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Secondary Change in GAD diagnosis The Anxiety and Related Disorders Interview Schedule for DSM-5 is a validated structured interview used to confirm the presence or absence of anxiety disorders and associated psychiatric diagnoses. Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
See also
  Status Clinical Trial Phase
Terminated NCT03420456 - Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Withdrawn NCT02382224 - Worry Exposure for Generalized Anxiety Disorder N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT02306356 - Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting N/A
Completed NCT01958788 - Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder N/A
Completed NCT01681329 - Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder N/A
Completed NCT01337713 - Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD) N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT01342120 - PHARMO Institute Seroquel Safety Study N/A
Completed NCT01203293 - Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector Phase 1
Completed NCT01971203 - Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat N/A
Completed NCT00961298 - An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Phase 4
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00744627 - Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults. Phase 3
Terminated NCT01244711 - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines Phase 4
Completed NCT00515242 - Therapeutic Massage for Generalized Anxiety Disorder Phase 1/Phase 2
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00537615 - An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers Phase 1
Completed NCT00620776 - Combined Treatment for Generalized Anxiety Disorder (GAD) Phase 2